Analysts Set Expectations for VERV FY2026 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Investment analysts at HC Wainwright issued their FY2026 EPS estimates for shares of Verve Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst M. Kapoor expects that the company will earn ($2.65) per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share.

Several other brokerages have also commented on VERV. Royal Bank of Canada decreased their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Canaccord Genuity Group upped their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Tuesday, April 15th. Guggenheim upped their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, April 15th. Finally, Cantor Fitzgerald raised shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, April 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verve Therapeutics has an average rating of “Buy” and a consensus price target of $25.75.

Verve Therapeutics Stock Performance

Shares of VERV stock opened at $4.61 on Tuesday. The firm’s 50 day moving average price is $4.71 and its 200-day moving average price is $5.84. Verve Therapeutics has a one year low of $2.86 and a one year high of $9.31. The firm has a market cap of $410.95 million, a P/E ratio of -1.87 and a beta of 1.82.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million.

Hedge Funds Weigh In On Verve Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VERV. Nisa Investment Advisors LLC raised its holdings in shares of Verve Therapeutics by 465.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company’s stock valued at $241,000 after purchasing an additional 35,214 shares in the last quarter. Impact Partnership Wealth LLC acquired a new stake in shares of Verve Therapeutics in the 4th quarter valued at $70,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Verve Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock valued at $101,000 after purchasing an additional 1,676 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Verve Therapeutics by 1.9% in the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock valued at $627,000 after purchasing an additional 2,093 shares in the last quarter. Finally, IFP Advisors Inc raised its holdings in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after purchasing an additional 8,237 shares in the last quarter. Hedge funds and other institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.